GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Debt-to-Equity

CAMP (Camp4 Therapeutics) Debt-to-Equity : -0.06 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Debt-to-Equity?

Camp4 Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.09 Mil. Camp4 Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.36 Mil. Camp4 Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-158.98 Mil. Camp4 Therapeutics's debt to equity for the quarter that ended in Sep. 2024 was -0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Camp4 Therapeutics's Debt-to-Equity or its related term are showing as below:

CAMP' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.16   Med: -0.08   Max: -0.06
Current: -0.06

During the past 2 years, the highest Debt-to-Equity Ratio of Camp4 Therapeutics was -0.06. The lowest was -0.16. And the median was -0.08.

CAMP's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs CAMP: -0.06

Camp4 Therapeutics Debt-to-Equity Historical Data

The historical data trend for Camp4 Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Debt-to-Equity Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23
Debt-to-Equity
-0.16 -0.10

Camp4 Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial N/A N/A -0.10 -0.07 -0.06

Competitive Comparison of Camp4 Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Camp4 Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Debt-to-Equity falls into.


Camp4 Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Camp4 Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.058 + 8.635) / -123.73
=-0.09

Camp4 Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.089 + 6.361) / -158.975
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics  (NAS:CAMP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Camp4 Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Camp4 Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Debt-to-Equity
Comparable Companies
CLYM ANIX CRBP SLS ATOS GALT ACOG CABA ZURA ARTV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Website
https://www.camp4tx.com
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.